fda decision on compounded tirzepatide says shortage is over after taking a second look Compounded Semaglutide & Tirzepatide 2025:

They are not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

In northwestern Pennsylvania, Highmark and UPMC Health Plan are the two predominant commercial health insurers

GHRP-6 also stimulates modest cortisol release through ACTH stimulation and mild prolactin elevation

TRIUMPH-1, the pivotal obesity trial, reported on May 21, 2026 , and TRIUMPH-2 (obesity in type 2 diabetes) and TRIUMPH-3 (obesity with established cardiovascular disease) both reported on July 23, 2026 so the core evidence package for this filing is in hand

Different medications can become tricky when it comes to finding an affordable option, especially when it comes to things such as weight loss where insurance companies vary and do or do not cover different things

If someone is offering it outside a clinical trial, be skeptical about what exactly you're getting